Salih Özçubukçu
Salih Özçubukçu has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Melek Parlak Khalily
Faculty of Arts and Science, Department of Chemistry, Yozgat Bozok University, Yozgat, Turkey
6 shared publications - Antoine Marion
Department of Chemistry, Middle East Technical University, 06800 Ankara, Turkey
4 shared publications - Carsten Bolm
Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, D-52074 Aachen, Germany
4 shared publications - Mehmet Seckin Kesici
Department of Chemistry , Middle East Technical University , Ankara , Türkiye
4 shared publications - Onur Alpturk
Istanbul Technical University
4 shared publications - Saniye Soylemez
Department of Biomedical Engineering, Faculty of Engineering
4 shared publications
Latest Publications
- 18 December 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (4) , 921-929
Effect of a partial loss of function MC3R mutation on MC3R+GHSR-1A heterodimer activity and RNF11 regulation
Purpose The melanocortin 3 receptor (MC3R) is a G-protein coupled receptor that has been identified as a regulator of energy balance mechanisms. In addition to its role in weight gain and appetite regulation mechanisms, recent studies have shown that MC3R is important for growth, puberty, circadian rhythms, and liver autophagy. In human populations, loss-of-function mutations of MC3R, particularly the Thr6Lys/Val81Ile MC3R variant are linked to early-onset obesity. This variant is characterized by decreased activity and reduced cAMP signaling capacity. Also, research has indicated that wild type (WT) MC3R and growth hormone secretagogue receptor 1A (GHSR-1A) receptors dimerize and increase MC3R-induced cAMP signaling. Moreover, MC3R can interact with ring finger protein 11 (RNF11), an E3 ligase. Methods In this study RNF11 was used to examine heterodimerization efficiency and functional properties of both WT and Thr6Lys/Val81Ile MC3R+GHSR-1A by using Förster Resonance Energy Transfer (FRET) technique and H187 EPAC cAMP detection biosensor. Results It was found that overexpression of RNF11 increased the WT MC3R’s heterodimerization efficiency and heterodimer specific MC3R cAMP production function, whereas no such effect was observed for Thr6Lys/Val81Ile MC3R. Conclusion Altered heterodimer function may help explain the signaling insufficiency of the Thr6Lys/Val81Ile MC3R haplotype.
- 18 December 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (4) , 921-929
Effect of a partial loss of function MC3R mutation on MC3R+GHSR-1A heterodimer activity and RNF11 regulation
Purpose The melanocortin 3 receptor (MC3R) is a G-protein coupled receptor that has been identified as a regulator of energy balance mechanisms. In addition to its role in weight gain and appetite regulation mechanisms, recent studies have shown that MC3R is important for growth, puberty, circadian rhythms, and liver autophagy. In human populations, loss-of-function mutations of MC3R, particularly the Thr6Lys/Val81Ile MC3R variant are linked to early-onset obesity. This variant is characterized by decreased activity and reduced cAMP signaling capacity. Also, research has indicated that wild type (WT) MC3R and growth hormone secretagogue receptor 1A (GHSR-1A) receptors dimerize and increase MC3R-induced cAMP signaling. Moreover, MC3R can interact with ring finger protein 11 (RNF11), an E3 ligase. Methods In this study RNF11 was used to examine heterodimerization efficiency and functional properties of both WT and Thr6Lys/Val81Ile MC3R+GHSR-1A by using Förster Resonance Energy Transfer (FRET) technique and H187 EPAC cAMP detection biosensor. Results It was found that overexpression of RNF11 increased the WT MC3R’s heterodimerization efficiency and heterodimer specific MC3R cAMP production function, whereas no such effect was observed for Thr6Lys/Val81Ile MC3R. Conclusion Altered heterodimer function may help explain the signaling insufficiency of the Thr6Lys/Val81Ile MC3R haplotype.
- 22 May 2025
- Published by Elsevier in Chemical Engineering Journal
- Vol. 516
Self-Assembled peptide nanofiber-based nanopharmaceutics for the treatment of viral infections
- 22 May 2025
- Published by Elsevier in Chemical Engineering Journal
- Vol. 516
Self-Assembled peptide nanofiber-based nanopharmaceutics for the treatment of viral infections
- Open Access
- 25 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 147-156
Application of Redox-Responsive Cysteine-Based Organogels as a Drug Delivery System for Doxorubicin
Cysteine derivatives having disulfide bonds in their side chains can be used as redox-responsive organogelators. The disulfide bond can be cleaved in the presence of certain reducing agents like thiol derivatives such as glutathione (GSH), which is a tripeptide that consists of cysteine, glutamic acid, and glycine. Studies show that cells of certain cancers have higher levels of glutathione due to increased production of reactive oxygen species (ROS). This feature allows targeted cancer therapy using glutathione-responsive drug delivery systems. This study showed the drug delivery property of l-Cys(t-dodecyl-sulfanyl)-OH and l-Cys-(StBu)-OH-based organogels. The drug-release properties of these organogels were measured in the presence of GSH and were compared with the drug-release property of the l-Cys-(tBu)-OH-based organogel. The biocompatibility of the organogelators was measured in vitro by MTT assay and the characterization of microstructures and gel behaviors were studied using transmission electron microscopy (TEM) imaging, X-ray diffraction spectroscopy (XRD), Fourier-transform infrared spectroscopy (FTIR), and rheological measurements. The results indicated that the organogelators were able to form nanofibers by hydrogen bonds and van der Waals interactions between their hydrophobic groups and were able to release doxorubicin in the presence of GSH. The in vitro biocompatibility studies did not show significant toxicity to the L929 cells for l-Cys-(StBu)-OH and showed low concentrations of l-Cys(t-dodecyl-sulfanyl)-OH.
- 25 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 147-156
Open AccessApplication of Redox-Responsive Cysteine-Based Organogels as a Drug Delivery System for Doxorubicin
Cysteine derivatives having disulfide bonds in their side chains can be used as redox-responsive organogelators. The disulfide bond can be cleaved in the presence of certain reducing agents like thiol derivatives such as glutathione (GSH), which is a tripeptide that consists of cysteine, glutamic acid, and glycine. Studies show that cells of certain cancers have higher levels of glutathione due to increased production of reactive oxygen species (ROS). This feature allows targeted cancer therapy using glutathione-responsive drug delivery systems. This study showed the drug delivery property of l-Cys(t-dodecyl-sulfanyl)-OH and l-Cys-(StBu)-OH-based organogels. The drug-release properties of these organogels were measured in the presence of GSH and were compared with the drug-release property of the l-Cys-(tBu)-OH-based organogel. The biocompatibility of the organogelators was measured in vitro by MTT assay and the characterization of microstructures and gel behaviors were studied using transmission electron microscopy (TEM) imaging, X-ray diffraction spectroscopy (XRD), Fourier-transform infrared spectroscopy (FTIR), and rheological measurements. The results indicated that the organogelators were able to form nanofibers by hydrogen bonds and van der Waals interactions between their hydrophobic groups and were able to release doxorubicin in the presence of GSH. The in vitro biocompatibility studies did not show significant toxicity to the L929 cells for l-Cys-(StBu)-OH and showed low concentrations of l-Cys(t-dodecyl-sulfanyl)-OH.
- Open Access
- 18 July 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (4) , 542-550
Human estrogen receptor alpha (ERα) targeted cyclic peptides inhibit cell growth and induce apoptosis in MCF-7 cells
Objectives: Human estrogen receptor alpha (ERα) is considered an important target, especially in the treatment of breast cancer, as it has a vital role in cancer development. ERα-targeted therapies generally target the ligand binding domain (LBD) of ERα. However, over time, cells develop resistance to this mechanism alternative approaches to inhibit ERα activity target ERα–DNA or ERα–cofactor interactions. Inhibitors of ERα–cofactor interactions are designed by targeting the hydrophobic hollow region of the receptor box LXXLL motif. Methods: In this context, helix-stabilized cyclic peptides (SPs) designed with in silico approaches were obtained by solid phase peptide synthesis. The effects of SPs on MCF-7 cells were examined with MTT and ATP, and qPCR and flow cytometry were used for further analysis. Results: Our results demonstrated that the SPs were effective only in MCF-7 cells expressing ERα. In addition, cyclic peptide combinations (SPCs) showed anti-proliferative and toxic effects on MCF-7 cells. The impact of SPCs with the highest inhibitory effect in MCF-7 cells on ERα-related genes and markers of apoptosis was revealed. Moreover, the flow cytometry analysis result used to examine apoptotic cells proved the apoptosis of SPCs in MCF-7 cells. Conclusions: These findings suggest that our novel SPs, which inhibit coactivator interactions of ERα, induce apoptosis of MCF-7 cells. Thus, considering this strong effect of SPs in the inhibition of receptors, it is pointed out that they can be further developed as an alternative to current clinical treatments or as an auxiliary approach in the generating of new targeted peptide-based therapies.
- 18 July 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (4) , 542-550
Open AccessHuman estrogen receptor alpha (ERα) targeted cyclic peptides inhibit cell growth and induce apoptosis in MCF-7 cells
Objectives: Human estrogen receptor alpha (ERα) is considered an important target, especially in the treatment of breast cancer, as it has a vital role in cancer development. ERα-targeted therapies generally target the ligand binding domain (LBD) of ERα. However, over time, cells develop resistance to this mechanism alternative approaches to inhibit ERα activity target ERα–DNA or ERα–cofactor interactions. Inhibitors of ERα–cofactor interactions are designed by targeting the hydrophobic hollow region of the receptor box LXXLL motif. Methods: In this context, helix-stabilized cyclic peptides (SPs) designed with in silico approaches were obtained by solid phase peptide synthesis. The effects of SPs on MCF-7 cells were examined with MTT and ATP, and qPCR and flow cytometry were used for further analysis. Results: Our results demonstrated that the SPs were effective only in MCF-7 cells expressing ERα. In addition, cyclic peptide combinations (SPCs) showed anti-proliferative and toxic effects on MCF-7 cells. The impact of SPCs with the highest inhibitory effect in MCF-7 cells on ERα-related genes and markers of apoptosis was revealed. Moreover, the flow cytometry analysis result used to examine apoptotic cells proved the apoptosis of SPCs in MCF-7 cells. Conclusions: These findings suggest that our novel SPs, which inhibit coactivator interactions of ERα, induce apoptosis of MCF-7 cells. Thus, considering this strong effect of SPs in the inhibition of receptors, it is pointed out that they can be further developed as an alternative to current clinical treatments or as an auxiliary approach in the generating of new targeted peptide-based therapies.
- 26 December 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (13) , 1707-1710
Rational design of an acceptor–chromophore–relay–catalyst tetrad assembly for water oxidation
We report the step-by-step synthesis of a precious metal-free acceptor–chromophore–relay–catalyst tetrad assembly that exhibits a turnover frequency (TOF) of 7.5 × 10−3 s−1 under neutral conditions. Transient absorption spectroscopic studies indicate that upon fullerenol incorporation into the investigated complexes, charge separation efficiency increases considerably.
- 26 December 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (13) , 1707-1710
Rational design of an acceptor–chromophore–relay–catalyst tetrad assembly for water oxidation
We report the step-by-step synthesis of a precious metal-free acceptor–chromophore–relay–catalyst tetrad assembly that exhibits a turnover frequency (TOF) of 7.5 × 10−3 s−1 under neutral conditions. Transient absorption spectroscopic studies indicate that upon fullerenol incorporation into the investigated complexes, charge separation efficiency increases considerably.
- Open Access
- 8 December 2023
- Published by MDPI AG in Proceedings
- Vol. 90 (1) , 17
Innovative Surface Designs for Sensing Applications
An essential problem in the field of advanced sensing systems is the search for innovative surfaces that can combine an effective immobilization of biomolecules or behave directly as an enzyme mimic with increased analytical performance
- 8 December 2023
- Published by MDPI AG in Proceedings
- Vol. 90 (1) , 17
Open AccessInnovative Surface Designs for Sensing Applications
An essential problem in the field of advanced sensing systems is the search for innovative surfaces that can combine an effective immobilization of biomolecules or behave directly as an enzyme mimic with increased analytical performance
- Open Access
- 22 October 2023
- Published by Wiley in Macromolecular Bioscience
- Vol. 24 (3) , e2300324
A Novel PEtOx‐Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery
This study focuses on creating a specialized nanogel for targeted drug delivery in cancer treatment, specifically targeting prostate cancer. This nanogel (referred to as SGK 636/Peptide 563/PEtOx nanogel) is created using hydrophilic poly(2‐ethyl‐2‐oxazoline) (PEtOx) through a combination of living/cationic ring‐opening polymerization (CROP) and alkyne‐azide cycloaddition (CuAAC) “click” chemical reactions. A fluorescent probe (BODIPY) is also conjugated with the nanogel to monitor drug delivery. The characterizations through 1H‐NMR, and FT‐IR, SEM, TEM, and DLS confirm the successful production of uniform, and spherical nanogels with controllable sizes (100 to 296 nm) and stability in physiological conditions. The biocompatibility of nanogels is evaluated using MTT cytotoxicity assays, revealing dose‐dependent cytotoxicity. Drug‐loaded nanogels exhibited significantly higher cytotoxicity against cancer cells in vitro compared to drug‐free nanogels. Targeting efficiency is examined using both peptide‐conjugated and peptide‐free nanogels, with the intracellular uptake of peptide 563‐conjugated nanogels by tumor cells being 60‐fold higher than that of nanogels without the peptide. The findings suggest that the prepared nanogel holds great potential for various drug delivery applications due to its ease of synthesis, tunable functionality, non‐toxicity, and enhanced intracellular uptake in the tumor region.
- 22 October 2023
- Published by Wiley in Macromolecular Bioscience
- Vol. 24 (3) , e2300324
Open AccessA Novel PEtOx‐Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery
This study focuses on creating a specialized nanogel for targeted drug delivery in cancer treatment, specifically targeting prostate cancer. This nanogel (referred to as SGK 636/Peptide 563/PEtOx nanogel) is created using hydrophilic poly(2‐ethyl‐2‐oxazoline) (PEtOx) through a combination of living/cationic ring‐opening polymerization (CROP) and alkyne‐azide cycloaddition (CuAAC) “click” chemical reactions. A fluorescent probe (BODIPY) is also conjugated with the nanogel to monitor drug delivery. The characterizations through 1H‐NMR, and FT‐IR, SEM, TEM, and DLS confirm the successful production of uniform, and spherical nanogels with controllable sizes (100 to 296 nm) and stability in physiological conditions. The biocompatibility of nanogels is evaluated using MTT cytotoxicity assays, revealing dose‐dependent cytotoxicity. Drug‐loaded nanogels exhibited significantly higher cytotoxicity against cancer cells in vitro compared to drug‐free nanogels. Targeting efficiency is examined using both peptide‐conjugated and peptide‐free nanogels, with the intracellular uptake of peptide 563‐conjugated nanogels by tumor cells being 60‐fold higher than that of nanogels without the peptide. The findings suggest that the prepared nanogel holds great potential for various drug delivery applications due to its ease of synthesis, tunable functionality, non‐toxicity, and enhanced intracellular uptake in the tumor region.
- Open Access
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (22) , 19656-19662
Tetraphenyl-1,4-dioxin and Tetraphenyl-pyrane-4-one: Old Molecules, New Insights
Aggregation-induced emission (AIE) is a phenomenon wherecertainmolecules or materials become highly luminescent when they aggregateor come together in a condensed state, such as a solid or a solution.Moreover, new molecules which show AIE properties are designed andsynthesized for various applications like imaging, sensing, and optoelectronics.2,3,5,6-Tetraphenylpyrazine (TPP) is one of the well-established examplesof AIE. Herein, 2,3,5,6-tetraphenyl-1,4-dioxin (TPD) and 2,3,4,5-tetraphenyl-4H-pyran-4-one (TPPO), which are old molecules with TPP similarity,were studied, and new insights in terms of structure and aggregation-causedquenching (ACQ)/AIE properties were gained by means of theoreticalcalculations. Those calculations performed on TPD and TPPO aimed toprovide a better understanding of their molecular structures and howthey affect their luminescence properties. This information couldbe used to design new materials with improved AIE properties or tomodify existing materials to overcome ACQ.
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (22) , 19656-19662
Open AccessTetraphenyl-1,4-dioxin and Tetraphenyl-pyrane-4-one: Old Molecules, New Insights
Aggregation-induced emission (AIE) is a phenomenon wherecertainmolecules or materials become highly luminescent when they aggregateor come together in a condensed state, such as a solid or a solution.Moreover, new molecules which show AIE properties are designed andsynthesized for various applications like imaging, sensing, and optoelectronics.2,3,5,6-Tetraphenylpyrazine (TPP) is one of the well-established examplesof AIE. Herein, 2,3,5,6-tetraphenyl-1,4-dioxin (TPD) and 2,3,4,5-tetraphenyl-4H-pyran-4-one (TPPO), which are old molecules with TPP similarity,were studied, and new insights in terms of structure and aggregation-causedquenching (ACQ)/AIE properties were gained by means of theoreticalcalculations. Those calculations performed on TPD and TPPO aimed toprovide a better understanding of their molecular structures and howthey affect their luminescence properties. This information couldbe used to design new materials with improved AIE properties or tomodify existing materials to overcome ACQ.
- Open Access
- 22 April 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 331-341
Downstream signalling of the disease‐associated mutations on GPR56/ADGRG1
GPR56/ADGRG1 is an adhesion G protein‐coupled receptor (GPCR) and mutations on this receptor cause cortical malformation due to the over‐migration of neural progenitor cells on brain surface. At pial surface, GPR56 interacts with collagen III, induces Rho‐dependent activation through Gα12/13 and inhibits the neuronal migration. In human glioma cells, GPR56 inhibits cell migration through Gαq/11‐dependent Rho pathway. GPR56‐tetraspanin complex is known to couple Gαq/11. GPR56 is an aGPCR that couples with various G proteins and signals through different downstream pathways. In this study, bilateral frontoparietal polymicrogyria (BFPP) mutants disrupting GPR56 function but remaining to be expressed on plasma membrane were used to study receptor signalling through Gα12, Gα13 and Gα11 with BRET biosensors. GPR56 showed coupling with all three G proteins and activated heterotrimeric G protein signalling upon stimulation with Stachel peptide. However, BFPP mutants showed different signalling defects for each G protein indicative of distinct activation and signalling properties of GPR56 for Gα12, Gα13 or Gα11. β‐arrestin recruitment was also investigated following the activation of GPR56 with Stachel peptide using BRET biosensors. N‐terminally truncated GPR56 showed enhanced β‐arrestin recruitment; however, neither wild‐type receptor nor BFPP mutants gave any measurable recruitment upon Stachel stimulation, pointing different activation mechanisms for β‐arrestin involvement.
- 22 April 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 331-341
Open AccessDownstream signalling of the disease‐associated mutations on GPR56/ADGRG1
GPR56/ADGRG1 is an adhesion G protein‐coupled receptor (GPCR) and mutations on this receptor cause cortical malformation due to the over‐migration of neural progenitor cells on brain surface. At pial surface, GPR56 interacts with collagen III, induces Rho‐dependent activation through Gα12/13 and inhibits the neuronal migration. In human glioma cells, GPR56 inhibits cell migration through Gαq/11‐dependent Rho pathway. GPR56‐tetraspanin complex is known to couple Gαq/11. GPR56 is an aGPCR that couples with various G proteins and signals through different downstream pathways. In this study, bilateral frontoparietal polymicrogyria (BFPP) mutants disrupting GPR56 function but remaining to be expressed on plasma membrane were used to study receptor signalling through Gα12, Gα13 and Gα11 with BRET biosensors. GPR56 showed coupling with all three G proteins and activated heterotrimeric G protein signalling upon stimulation with Stachel peptide. However, BFPP mutants showed different signalling defects for each G protein indicative of distinct activation and signalling properties of GPR56 for Gα12, Gα13 or Gα11. β‐arrestin recruitment was also investigated following the activation of GPR56 with Stachel peptide using BRET biosensors. N‐terminally truncated GPR56 showed enhanced β‐arrestin recruitment; however, neither wild‐type receptor nor BFPP mutants gave any measurable recruitment upon Stachel stimulation, pointing different activation mechanisms for β‐arrestin involvement.